Search Results - "Hart, Lowell L"

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study by HOCHSTER, Howard S, HART, Lowell L, SCHWARTZBERG, Lee, HEDRICK, Eric, RAMANATHAN, Ramesh K, CHILDS, Barrett H, HAINSWORTH, John D, COHN, Allen L, WONG, Lucas, FEHRENBACHER, Louis, ABUBAKR, Yousif, WASIF SAIF, M

“…To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic…”
Get full text

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer by KHAMBATA-FORD, Shirin, HARBISON, Christopher T, HART, Lowell L, AWAD, Melissa, XU, Li-An, HORAK, Christine E, DAKHIL, Shaker, HERMANN, Robert C, LYNCH, Thomas J, WEBER, Martin R

“…PURPOSE The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with markers predictive…”
Get full text

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial by Saad, Fred, Dr Prof, Fizazi, Karim, Prof, Jinga, Viorel, Prof, Efstathiou, Eleni, MD, Fong, Peter C, MD, Hart, Lowell L, MD, Jones, Robert, MD, McDermott, Raymond, MD, Wirth, Manfred, Prof, Suzuki, Kazuhiro, Prof, MacLean, David B, MD, Wang, Ling, PhD, Akaza, Hideyuki, Prof, Nelson, Joel, Prof, Scher, Howard I, Prof, Dreicer, Robert, Prof, Webb, Iain J, MD, de Wit, Ronald, Prof

“…Summary Background Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated…”
Get full text

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma by Berdeja, Jesus G, Hart, Lowell L, Mace, Joseph R, Arrowsmith, Edward R, Essell, James H, Owera, Rami S, Hainsworth, John D, Flinn, Ian W

“…The purpose of this study was to assess the safety and efficacy of the combination of panobinostat and carfilzomib in patients with relapsed/refractory…”
Get full text

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial by ROTHENBERG, Mace L, OZA, Amit M, LE BAIL, Nathalie, HALLER, Daniel G, BIGELOW, Robert H, BERLIN, Jordan D, MARSHALL, John L, RAMANATHAN, Ramesh K, HART, Lowell L, GUPTA, Sunil, GARAY, Carlos A, BURGER, Brent G

“…In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with…”
Get full text

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients by Paoletti, Costanza, Regan, Meredith M., Niman, Samuel M., Dolce, Emily M., Darga, Elizabeth P., Liu, Minetta C., Marcom, P. Kelly, Hart, Lowell L., Smith, John W., Tedesco, Karen L., Amir, Eitan, Krop, Ian E., DeMichele, Angela M., Goodwin, Pamela J., Block, Margaret, Aung, Kimberly, Brown, Martha E., McCormack, Robert T., Hayes, Daniel F.

“…Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen…”
Get full text

Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer by SOCINSKI, Mark A, WEISSMAN, Charles, HART, Lowell L, BECK, J. Thaddeus, CHOKSI, Janak K, HANSON, John P, PRAGER, Diane, MONBERG, Matthew J, ZHISHEN YE, OBASAJU, Coleman K

“…Given the activity and tolerability of pemetrexed/platinum combinations in non-small-cell lung cancer, and the success of novel therapeutic strategies employed…”
Get full text

Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer by LILENBAUM, Rogerio, SOCINSKI, Mark A, ALTORKI, Nasser K, HART, Lowell L, KERESZTES, Roger S, HARIHARAN, Subramanian, MORRISON, Mark E, FAYYAD, Rana, BONOMI, Phillip

“…Trials combining irinotecan/docetaxel and irinotecan/gemcitabine in second-line treatment of non-small-cell lung cancer (NSCLC) have yielded promising results…”
Get full text

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors by Von Hoff, Daniel D, Mita, Monica M, Ramanathan, Ramesh K, Weiss, Glen J, Mita, Alain C, LoRusso, Patricia M, Burris, 3rd, Howard A, Hart, Lowell L, Low, Susan C, Parsons, Donald M, Zale, Stephen E, Summa, Jason M, Youssoufian, Hagop, Sachdev, Jasgit C

“…First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen…”
Get full text

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study by Hart, Lowell L., Ferrarotto, Renata, Andric, Zoran G., Beck, J. Thaddeus, Subramanian, Janakiraman, Radosavljevic, Davorin Z., Zaric, Bojan, Hanna, Wahid T., Aljumaily, Raid, Owonikoko, Taofeek K., Verhoeven, Didier, Xiao, Jie, Morris, Shannon R., Antal, Joyce M., Hussein, Maen A.

“…Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current…”
Get full text

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial by O’Shaughnessy, Joyce, Petrakova, Katarina, Sonke, Gabe S., Conte, Pierfranco, Arteaga, Carlos L., Cameron, David A., Hart, Lowell L., Villanueva, Cristian, Jakobsen, Erik, Beck, Joseph T., Lindquist, Deborah, Souami, Farida, Mondal, Shoubhik, Germa, Caroline, Hortobagyi, Gabriel N.

“…Purpose Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. Methods Postmenopausal women…”
Get full text

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours by Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, Jong, Floris A., Tsimberidou, Apostolia Maria

“…Aim Preclinical evidence suggests that oxidized macrophage migration inhibitory factor (oxMIF) may be involved in carcinogenesis. This phase 1 study…”
Get full text

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial by Autio, Karen A, Dreicer, Robert, Anderson, Justine, Garcia, Jorge A, Alva, Ajjai, Hart, Lowell L, Milowsky, Matthew I, Posadas, Edwin M, Ryan, Charles J, Graf, Ryon P, Dittamore, Ryan, Schreiber, Nicole A, Summa, Jason M, Youssoufian, Hagop, Morris, Michael J, Scher, Howard I

“…Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is clinically effective, and the selective…”
Get more information

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial by Sonke, Gabe S., Hart, Lowell L., Campone, Mario, Erdkamp, Frans, Janni, Wolfgang, Verma, Sunil, Villanueva, Cristian, Jakobsen, Erik, Alba, Emilio, Wist, Erik, Favret, Anne M., Bachelot, Thomas, Hegg, Roberto, Wheatley-Price, Paul, Souami, Farida, Sutradhar, Santosh, Miller, Michelle, Germa, Caroline, Burris, Howard A.

“…Purpose Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2− advanced breast cancer. Methods 668…”
Get full text

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer by BERLIN, Jordan, BENDELL, Johanna C, GRAHAM, Richard A, BRAY, Gordon L, LOW, Jennifer A, HART, Lowell L, FIRDAUS, Irfan, GORE, Ira, HERMANN, Robert C, MULCAHY, Mary F, ZALUPSKI, Mark M, MACKEY, Howard M, YAUCH, Robert L

“…Vismodegib, a Hedgehog pathway inhibitor, has preclinical activity in colorectal cancer (CRC) models. This trial assessed the efficacy, safety, and…”
Get full text

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma by Ott, Patrick A., Pavlick, Anna C., Johnson, Douglas B., Hart, Lowell L., Infante, Jeffrey R., Luke, Jason J., Lutzky, Jose, Rothschild, Neal E., Spitler, Lynn E., Cowey, C. Lance, Alizadeh, Aaron R., Salama, April K., He, Yi, Hawthorne, Thomas R., Bagley, Rebecca G., Zhang, Joshua, Turner, Christopher D., Hamid, Omid

“…Background Glembatumumab vedotin is an antibody‐drug conjugate that produced preliminary clinical activity against advanced melanoma in a phase 1…”
Get full text

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy by Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.

“…Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment in patients with KRAS wild‐type (KRAS WT), metastatic colorectal cancer…”
Get full text

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes by Grivas, Petros, Mortazavi, Amir, Picus, Joel, Hahn, Noah M., Milowsky, Matthew I., Hart, Lowell L., Alva, Ajjai, Bellmunt, Joaquim, Pal, Sumanta K., Bambury, Richard M., O’Donnell, Peter H., Gupta, Sumati, Guancial, Elizabeth A., Sonpavde, Guru P., Faltaos, Demiana, Potvin, Diane, Christensen, James G., Chao, Richard C., Rosenberg, Jonathan E.

“…Background The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating…”
Get full text

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer by Bendell, Johanna C., Hochster, Howard, Hart, Lowell L., Firdaus, Irfan, Mace, Joseph R., McFarlane, Joshua J., Kozloff, Mark, Catenacci, Daniel, Hsu, Jessie J., Hack, Stephen P., Shames, David S., Phan, See‐Chun, Koeppen, Hartmut, Cohn, Allen L.

“…Background Dysregulated hepatocyte growth factor/mesenchymal‐epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular…”
Get full text

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 by GNANT, Michael, BASELGA, Jose, GEBERTH, Matthias, HART, Lowell L, HADJI, Peyman, EL-HASHIMY, Mona, RAO, Shantha, TARAN, Tetiana, SAHMOUD, Tarek, LEBWOHL, David, CAMPONE, Mario, PRITCHARD, Kathleen I, RUGO, Hope S, NOGUCHI, Shinzaburo, BURRIS, Howard A, PICCART, Martine, HORTOBAGYI, Gabriel N, EAKLE, Janice, MUKAI, Hirofumi, IWATA, Hiroji

“…Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor-positive breast cancer progressing…”
Get full text